[go: up one dir, main page]

FR2749857B1 - GENERATION OF IN VIVO REPLICATIVE MOLECULES - Google Patents

GENERATION OF IN VIVO REPLICATIVE MOLECULES

Info

Publication number
FR2749857B1
FR2749857B1 FR9607273A FR9607273A FR2749857B1 FR 2749857 B1 FR2749857 B1 FR 2749857B1 FR 9607273 A FR9607273 A FR 9607273A FR 9607273 A FR9607273 A FR 9607273A FR 2749857 B1 FR2749857 B1 FR 2749857B1
Authority
FR
France
Prior art keywords
generation
molecules
vivo
replicative molecules
vivo replicative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9607273A
Other languages
French (fr)
Other versions
FR2749857A1 (en
Inventor
Prehaud Helene Leblois
Michel Perricaudet
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9607273A priority Critical patent/FR2749857B1/en
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP97925133A priority patent/EP0906443B1/en
Priority to CZ0402398A priority patent/CZ296600B6/en
Priority to AT97925133T priority patent/ATE301721T1/en
Priority to AU30377/97A priority patent/AU726442B2/en
Priority to IL12743097A priority patent/IL127430A0/en
Priority to US09/194,960 priority patent/US6630322B1/en
Priority to ES97925133T priority patent/ES2248849T3/en
Priority to BR9709700A priority patent/BR9709700A/en
Priority to HU9902585A priority patent/HU224175B1/en
Priority to DE69733948T priority patent/DE69733948T2/en
Priority to SK1698-98A priority patent/SK169898A3/en
Priority to CA002257916A priority patent/CA2257916A1/en
Priority to JP10501269A priority patent/JP2000511779A/en
Priority to PCT/FR1997/000914 priority patent/WO1997047757A1/en
Priority to ZA9705134A priority patent/ZA975134B/en
Publication of FR2749857A1 publication Critical patent/FR2749857A1/en
Application granted granted Critical
Publication of FR2749857B1 publication Critical patent/FR2749857B1/en
Priority to NO985739A priority patent/NO985739D0/en
Priority to DK97925133T priority patent/DK0906443T3/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)

Abstract

The invention discloses circular and replicating DNA molecules, useful in gene therapy, as well as a particularly efficient method for generating them in situ from a viral vector.
FR9607273A 1996-06-12 1996-06-12 GENERATION OF IN VIVO REPLICATIVE MOLECULES Expired - Fee Related FR2749857B1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (en) 1996-06-12 1996-06-12 GENERATION OF IN VIVO REPLICATIVE MOLECULES
SK1698-98A SK169898A3 (en) 1996-06-12 1997-05-23 Circular replicative dna molecules, viral vector, cell modified by insertion of viral vector, pharmaceutical composition containing a viral vector, process for the preparation of circular replicative dna and use of viral vector
AT97925133T ATE301721T1 (en) 1996-06-12 1997-05-23 IN VIVO PRODUCTION OF REPLICATIVE MOLECULES
AU30377/97A AU726442B2 (en) 1996-06-12 1997-05-23 Generation of replicative molecules in vivo
IL12743097A IL127430A0 (en) 1996-06-12 1997-05-23 Generating replicating moleucules in vivo
US09/194,960 US6630322B1 (en) 1996-06-12 1997-05-23 Generating replicating molecules in vivo
ES97925133T ES2248849T3 (en) 1996-06-12 1997-05-23 GENERATION OF REPLICATING MOLECULES "IN VIVO".
BR9709700A BR9709700A (en) 1996-06-12 1997-05-23 Viral vector cell pharmaceutical composition process of preparing in situ replicative circular DNA molecules using a viral vector process for the transfer of nucleic acids to a replicating circular DNA molecule
HU9902585A HU224175B1 (en) 1996-06-12 1997-05-23 Virus vectors for generating circular replicating molecules in situ
JP10501269A JP2000511779A (en) 1996-06-12 1997-05-23 In vivo generation of replicating molecules
EP97925133A EP0906443B1 (en) 1996-06-12 1997-05-23 Generating replicating molecules in vivo
CZ0402398A CZ296600B6 (en) 1996-06-12 1997-05-23 Viral vector containing replicating DNA, process for preparing such DNA and pharmaceutical composition in which the viral vector is comprised
DE69733948T DE69733948T2 (en) 1996-06-12 1997-05-23 IN VIVO MANUFACTURE OF REPLICATIVES MOLECULES
PCT/FR1997/000914 WO1997047757A1 (en) 1996-06-12 1997-05-23 Generating replicating molecules in vivo
CA002257916A CA2257916A1 (en) 1996-06-12 1997-05-23 Generating replicating molecules in vivo
ZA9705134A ZA975134B (en) 1996-06-12 1997-06-10 Generation of replicative molecules in vivo.
NO985739A NO985739D0 (en) 1996-06-12 1998-12-08 Generation of replicative molecules in vivo
DK97925133T DK0906443T3 (en) 1996-06-12 2005-12-19 Generation of replicating molecules in vivo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (en) 1996-06-12 1996-06-12 GENERATION OF IN VIVO REPLICATIVE MOLECULES

Publications (2)

Publication Number Publication Date
FR2749857A1 FR2749857A1 (en) 1997-12-19
FR2749857B1 true FR2749857B1 (en) 1998-08-14

Family

ID=9492965

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9607273A Expired - Fee Related FR2749857B1 (en) 1996-06-12 1996-06-12 GENERATION OF IN VIVO REPLICATIVE MOLECULES

Country Status (18)

Country Link
US (1) US6630322B1 (en)
EP (1) EP0906443B1 (en)
JP (1) JP2000511779A (en)
AT (1) ATE301721T1 (en)
AU (1) AU726442B2 (en)
BR (1) BR9709700A (en)
CA (1) CA2257916A1 (en)
CZ (1) CZ296600B6 (en)
DE (1) DE69733948T2 (en)
DK (1) DK0906443T3 (en)
ES (1) ES2248849T3 (en)
FR (1) FR2749857B1 (en)
HU (1) HU224175B1 (en)
IL (1) IL127430A0 (en)
NO (1) NO985739D0 (en)
SK (1) SK169898A3 (en)
WO (1) WO1997047757A1 (en)
ZA (1) ZA975134B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (en) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
WO2011071476A2 (en) * 2008-11-14 2011-06-16 Life Technologies Corporation Compositions and methods for engineering cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
DE4228458A1 (en) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronic expression units and their use
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
EP0632054A1 (en) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Regulation of site-specific recombination by site-specific recombinase/nuclear receptor fusion proteins
JP4216350B2 (en) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 Recombinant DNA viral vector for animal cell infection
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6156497A (en) * 1996-01-05 2000-12-05 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
ZA975134B (en) 1997-12-31
US6630322B1 (en) 2003-10-07
AU726442B2 (en) 2000-11-09
NO985739L (en) 1998-12-08
IL127430A0 (en) 1999-10-28
SK169898A3 (en) 1999-07-12
DE69733948T2 (en) 2006-06-08
CZ402398A3 (en) 1999-03-17
JP2000511779A (en) 2000-09-12
CZ296600B6 (en) 2006-04-12
CA2257916A1 (en) 1997-12-18
ES2248849T3 (en) 2006-03-16
WO1997047757A1 (en) 1997-12-18
HUP9902585A3 (en) 2001-11-28
ATE301721T1 (en) 2005-08-15
AU3037797A (en) 1998-01-07
FR2749857A1 (en) 1997-12-19
BR9709700A (en) 1999-08-10
HU224175B1 (en) 2005-06-28
DK0906443T3 (en) 2005-12-19
HUP9902585A2 (en) 1999-11-29
EP0906443A1 (en) 1999-04-07
EP0906443B1 (en) 2005-08-10
NO985739D0 (en) 1998-12-08
DE69733948D1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
CY1105963T1 (en) CAPSOMEPIDIAN VACCINE COMPOSITIONS AND METHODS OF USE
DE69933653D1 (en) RIBOZYMS THAT ARE CAPABLE OF RESTRICTING THE EXPRESSION OF THE CCR5 RECEPTOR
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
EP0757717A4 (en) PAPILLOMAVIRUS VACCINES
IL181695A0 (en) Methods for cultivating cells and propagating viruses
NO20002504D0 (en) Adenovirus vectors and method of reducing homologous recombination phenomena
DK1123414T3 (en) Antisense modulation of integrin alpha 4. expression
FI961666A7 (en) Gene therapy for restenosis using an adenovirus vector
WO2002097056A3 (en) Method for generating replication defective viral vectors that are helper free
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
DK1082423T3 (en) Cyclin E2 genes and proteins
FR2749857B1 (en) GENERATION OF IN VIVO REPLICATIVE MOLECULES
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
DE69834283D1 (en) Apparatus for recovering, refining and storing hydrogen gas
ATE343329T1 (en) METHOD FOR PRODUCING PARBOILED RICE AND CHARGING PARBOILED RICE
DE69938643D1 (en) Method and apparatus for generating document type definitions
MXPA98005238A (en) Cardiovascular and thrombus imaging agents, methods and kits.
DE69726602D1 (en) Hepatitis b inhibitoren
DE60039120D1 (en) CATALYTIC RNAS WITH AMINOACYLATING ACTIVITY
DE59611293D1 (en) PROTEIN WITH DNASE ACTIVITY
ATE301720T1 (en) CATHEPSIN-L, ITS PREPROFORM AND THE CORRESPONDING PROPEPTIDE FROM CILIATES
DE60024442D1 (en) USE OF VIRAL VECTORS AND LOADED MOLECULES FOR GENE THERAPY
ES2175184T3 (en) VIRUSES THAT EXPRESS TOXIC PROTEINS AND PRODUCING CELLULAR LINES.
ES2130073A1 (en) PROCESS FOR OBTAINING beta -D-GALACTOPYRANOSYL-XYLOSES USABLE FOR THE DIAGNOSTIC EVALUATION OF INTESTINAL LACTASE
UA25582C2 (en) MEANS FOR TREATMENT OF HEMATOCYTOPENIC REACTIONS OF WARM-BLOOD ORGANISMS

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080229